Johnson Johnson

PHARMACEUTICAL RESEARCH

& DEVELOPMENT, L.L.C.

1125 Trenton-Harbourton Road PO Box 200, Titusville, NJ 08560

0 6 8 8 '03 FEB 27 A10:59 February 26, 2003

Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Dr. Charles Hoiberg

Re: Comments on Draft Guidance M4 Common Technical Document – Quality: Ouestions and Answers/Location Issues

Dear Dr. Hoiberg:

The above referenced FDA draft guidance M4 Common Technical Document – Quality: Questions and Answers/Location Issues, dated September 12, 2002 and published in the Federal Register on December 30, 2002 has been reviewed by scientists at Johnson & Johnson Pharmaceutical Research and Development, LLC. The following comment has been identified and is summarized as follows:

Under Section 2. General Issues, 2.3 Table of Contents Formatting (page 5) under Module 3, last sentence in the first paragraph, the draft guidance states "The lower Table of Contents described under 2.3 Document Pagination and Segregation...".

The Document Pagination and Segregation is incorrectly crossed referenced as section 2.3. The cross reference should be revised to read 2.2 Document Pagination and Segregation.

We greatly appreciate the opportunity to comment on this draft guidance and look forward to working closely with the FDA on future documents. If you have questions or need assistance, please contact me directly at 609/730-3425.

Sincerely,

Sue Halley

Manager

Regulatory Sciences

Global Chem-Pharm Regulatory Affairs

Hale

Johnson & Johnson Pharmaceutical Research and Development, LLC

020-0509

C3